Langer Thorsten, Beck Joern-Dirk, Gravou-Apostulatou Chara, Lang Peter, Handgretinger Rupert, Greil Johann
Division of Pediatric Oncology, Hospital for Children and Adolescents, University of Erlangen, Germany.
Pediatr Transplant. 2003 Dec;7(6):494-6. doi: 10.1046/j.1399-3046.2003.00095.x.
We report on a 9-yr-old boy suffering from primary refractory AML. Remission was not achieved after two courses of induction therapy, leading to prolonged aplasia for more than 3 months and severe infection. Therefore, the boy was treated with a reduced intensity conditioning regimen consisting of fludarabine, cyclophosphamide and OKT3. Megadose transplantation of highly enriched CD34+ peripheral stem cells from his HLA-identical brother, followed on day +11 by a boost of unmanipulated bone marrow, was performed. Regeneration of donor hematopoiesis was rapid and led to resolution of infection. No additional donor lymphocyte infusions were necessary. More than 4 1/2 yr after the transplant the boy remains in complete continuous remission with no evidence for chronic GvHD or other late effects. Therefore, we conclude that reduced intensity conditioning in combination with allogeneic megadose stem cell transplantation and bone marrow boost may have helped to achieve cure from primary refractory AML as well as a good quality of life for this boy.
我们报告了一名9岁患有原发性难治性急性髓细胞白血病(AML)的男孩。经过两个疗程的诱导治疗后未达到缓解,导致长期再生障碍超过3个月并伴有严重感染。因此,该男孩接受了由氟达拉滨、环磷酰胺和OKT3组成的降低强度预处理方案。进行了来自其 HLA 相同哥哥的高富集 CD34+外周干细胞大剂量移植,并在第 +11 天接着输注未经处理的骨髓进行强化。供体造血功能迅速恢复并使感染得到解决。无需额外的供体淋巴细胞输注。移植后超过4年半,该男孩仍处于完全持续缓解状态,没有慢性移植物抗宿主病(GvHD)或其他晚期效应的证据。因此,我们得出结论,降低强度预处理联合异基因大剂量干细胞移植和骨髓强化可能有助于治愈原发性难治性AML,并为该男孩带来良好的生活质量。